Genomic and Proteomic Biomarkers for Cancer: a Multitude of Opportunities

Overview

Journal Biochim Biophys Acta

Specialties Biochemistry
Biophysics

Date 2009 May 2

PMID 19406210

Citations 39

Authors

Michael A Tainsky

Affiliations

Soon will be listed here.

Abstract

Biomarkers are molecular indicators of a biological status, and as biochemical species can be assayed to evaluate the presence of cancer and therapeutic interventions. Through a variety of mechanisms cancer cells provide the biomarker material for their own detection. Biomarkers may be detectable in the blood, other body fluids, or tissues. The expectation is that the level of an informative biomarker is related to the specific type of disease present in the body. Biomarkers have potential both as diagnostic indicators and monitors of the effectiveness of clinical interventions. Biomarkers are also able to stratify cancer patients to the most appropriate treatment. Effective biomarkers for the early detection of cancer should provide a patient with a better outcome which in turn will translate into more efficient delivery of healthcare. Technologies for the early detection of cancer have resulted in reductions in disease-associated mortalities from cancers that are otherwise deadly if allowed to progress. Such screening technologies have proven that early detection will decrease the morbidity and mortality from cancer. An emerging theme in biomarker research is the expectation that panels of biomarker analytes rather than single markers will be needed to have sufficient sensitivity and specificity for the presymptomatic detection of cancer. Biomarkers may provide prognostic information of disease enabling interventions using targeted therapeutic agents as well as course-corrections in cancer treatment. Novel genomic, proteomic and metabolomic technologies are being used to discover and validate tumor biomarkers individually and in panels.

Citing Articles

Applications of Digital Enzyme-Linked Immunosorbent Assays in Ophthalmology.

Yu H, Song J, Li J, Qi Y, Fan Z, Liu Q Cell Biochem Biophys. 2024; 83(1):215-220.

PMID: 39333452 PMC: 11870898. DOI: 10.1007/s12013-024-01515-2.

Exploring heterogeneous expression of beta-actin (ACTB) in bladder cancer by producing a monoclonal antibody 6D6.

Zareinejad M, Faghih Z, Ramezani A, Safaei A, Ghaderi A BMC Urol. 2024; 24(1):124.

PMID: 38867273 PMC: 11167769. DOI: 10.1186/s12894-024-01489-6.

Spatial Proteomics for the Molecular Characterization of Breast Cancer.

Brozova K, Hantusch B, Kenner L, Kratochwill K Proteomes. 2023; 11(2).

PMID: 37218922 PMC: 10204503. DOI: 10.3390/proteomes11020017.

An Inflection Point in Cancer Protein Biomarkers: What was and What's Next.

Barker A, Alba M, Mallick P, Agus D, Lee J Mol Cell Proteomics. 2023; 22(7):100569.

PMID: 37196763 PMC: 10388583. DOI: 10.1016/j.mcpro.2023.100569.

Isolation of Single-Domain Antibodies to Transmembrane Proteins Using Magnetized Yeast Cell Targets.

Bacon K, Menegatti S, Rao B Methods Mol Biol. 2022; 2446:95-119.

PMID: 35157270 DOI: 10.1007/978-1-0716-2075-5_5.

References

Borchert G, Lanier W, Davidson B . RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol. 2006; 13(12):1097-101. DOI: 10.1038/nsmb1167. View

Esteller M, Corn P, Baylin S, Herman J . A gene hypermethylation profile of human cancer. Cancer Res. 2001; 61(8):3225-9. View

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G . Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005; 65(17):7591-5. DOI: 10.1158/0008-5472.CAN-05-1855. View

Ross D, Hughes T . Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders. Pathology. 2008; 40(3):231-46. DOI: 10.1080/00313020801916172. View

Tomkiel J, Alansari H, Tang N, Virgin J, Yang X, VandeVord P . Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer. Clin Cancer Res. 2002; 8(3):752-8. PMC: 5604237. View

Li J, Zhang Z, Rosenzweig J, Wang Y, Chan D . Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem. 2002; 48(8):1296-304. View

Draghici S, Khatri P, Tarca A, Amin K, Done A, Voichita C . A systems biology approach for pathway level analysis. Genome Res. 2007; 17(10):1537-45. PMC: 1987343. DOI: 10.1101/gr.6202607. View

Wienholds E, Kloosterman W, Miska E, Alvarez-Saavedra E, Berezikov E, de Bruijn E . MicroRNA expression in zebrafish embryonic development. Science. 2005; 309(5732):310-1. DOI: 10.1126/science.1114519. View

10.

Riggi N, Stamenkovic I . The Biology of Ewing sarcoma. Cancer Lett. 2007; 254(1):1-10. DOI: 10.1016/j.canlet.2006.12.009. View

11.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

12.

Greenman C, Stephens P, Smith R, Dalgliesh G, Hunter C, Bignell G . Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446(7132):153-8. PMC: 2712719. DOI: 10.1038/nature05610. View

13.

Lugo T, Pendergast A, Muller A, Witte O . Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990; 247(4946):1079-82. DOI: 10.1126/science.2408149. View

14.

Romana S, Poirel H, Leconiat M, Flexor M, Mauchauffe M, Jonveaux P . High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood. 1995; 86(11):4263-9. View

15.

Baggerly K, Morris J, Edmonson S, Coombes K . Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst. 2005; 97(4):307-9. DOI: 10.1093/jnci/dji008. View

16.

Bean J, Riely G, Balak M, Marks J, Ladanyi M, Miller V . Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res. 2008; 14(22):7519-25. PMC: 2596620. DOI: 10.1158/1078-0432.CCR-08-0151. View

17.

Anderson N, Anderson N . The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002; 1(11):845-67. DOI: 10.1074/mcp.r200007-mcp200. View

18.

Hou M, Chen Y, Tseng T, Lin C, Chen M, Huang C . Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer. Kaohsiung J Med Sci. 1999; 15(9):520-8. View

19.

Vogel V, Costantino J, Wickerham D, Cronin W, Cecchini R, Atkins J . Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006; 295(23):2727-41. DOI: 10.1001/jama.295.23.joc60074. View

20.

Chim C, Pang R, Fung T, Choi C, Liang R . Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia. 2007; 21(12):2527-36. DOI: 10.1038/sj.leu.2404939. View